Inhibition of hepatic sulfatase‐2 In Vivo: A novel strategy to correct diabetic dyslipidemia
H. Carlijne Hassing, Hans Mooij, Shuling Guo, Brett P. Monia, Keyang Chen, Wim Kulik, Geesje M. Dallinga‐Thie, Max Nieuwdorp, Erik S.G. Stroes, Kevin Jon Williams – 11 January 2012 – Type 2 diabetes mellitus (T2DM) impairs hepatic clearance of atherogenic postprandial triglyceride‐rich lipoproteins (TRLs). We recently reported that livers from T2DM db/db mice markedly overexpress the heparan sulfate glucosamine‐6‐O‐endosulfatase‐2 (SULF2), an enzyme that removes 6‐O sulfate groups from heparan sulfate proteoglycans (HSPGs) and suppresses uptake of TRLs by cultured hepatocytes.